Salma Jabbour
Radiation Oncology · New Brunswick, NJNPI 1184707234
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $132,199 of the $163,115 with a category attached, or 81.0%. Merck accounts for 80.6% of it on its own, with 8 other manufacturers making up the rest. Among radiation oncology clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 95 payments — averaging $1717.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$131K
- AstraZeneca$15K
- Janssen Research & Development, LLC$7K
- Beigene Switzerland GmbH$6K
- Novocure Inc.$2K
- Astrazeneca UK Limited$1K
- plus $184 from 3 others
Across 125 payments — averaging $21,672 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$2.5M
- Beigene Switzerland GmbH$124K
- Regeneron$66K
- E.r. Squibb & Sons, L.L.C.$43K
- Organon$5
What the payments were for
- Consulting fees$132,19981%
- Speaking & faculty fees$8,8215%
- Travel & lodging$20,13512%
- Food & beverage$1,9201%
- Education$400%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 73 | $131,400 |
| AstraZeneca | 12 | $15,422 |
| Janssen Research & Development, LLC | 2 | $6,869 |
| Beigene Switzerland GmbH | 1 | $5,625 |
| Novocure Inc. | 2 | $2,160 |
| Astrazeneca UK Limited | 2 | $1,456 |
| Elekta, Inc. | 1 | $125 |
| EMD Serono, Inc. | 1 | $40 |
| Novartis | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$163,115 in reported general payments places this provider in the 95th percentile of 132 radiation oncology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lidocaine Hcl ViscousLidocaine Hcl | 11 | $233 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in New Brunswick
- Sharad GoyalNew Brunswick$3K
- Atif KhanNew Brunswick$2K
- Bruce HafftyNew Brunswick$1K
- Lara HathoutNew Brunswick$592
- Michael GreenbergCherry Hill$335K
- Glen GejermanHackensack$180K
- Marc RudoltzWest Orange$166K
- Edward SoffenMonroe Twp$50K
- Adnan DanishWayne$45K
- Timothy ChenPennington$43K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.